Andrey is a lawyer in our firm’s Capital Markets department, who specializes in advising and providing ongoing assistance to companies on matters pertaining to capital markets, securities law and corporate law.
Andrey provides ongoing legal counsel to Israeli and foreign companies on matters involving capital markets, financial regulations, commercial law and corporate governance, and represents clients before the Israel Securities Authority and the Capital Market Division. Andrey has extensive experience establishing and counseling investments funds, hedge funds and portfolio management and consulting firms. Andrey counsels clients on the commercial aspects of diverse transactions, including investment and financing transactions.
Prior to joining Barnea & Co. Andrey worked at a law firm specializing in capital markets and commercial law, and at the Bank of Israel, where he was involved in regulatory reforms relating to the capital market in Israel.
Tel-Aviv University (LL.B, BA in economics) 2010
Member of the Israel Bar Association since 2011
News and updates - Andrey Yanai:
Cellect Biotechnology Completed a Nasdaq IPO
On 31st July 2016 Cellect Biotechnology announced that it has completed its Nasdaq IPO, raising $8.4 million. Cellect Biotechnology will be traded on Nasdaq in parallel with its listing on the Tel Aviv Stock Exchange. Barnea & Co. represented a group of US underwriters, led by H.C. Wainwright & Co., LLC, in the process of submission by Cellect Biotechnology of a prospectus for the Nasdaq listing. Cellect Biotechnology develops innovative technologies in the stem cells sphere.
Proposal to reconsider the activist regulatory model of the Israel Securities Authority
An article by Adv. Zvi Gabbay and Andrey Yanai on the proposal to reconsider the activist regulatory model of the Israel Securities Authority applied to the public companies, allowing them to enjoy wider business and legal maneuvering room.